As a computer scientist, he knew that to make a real impact with image analysis there were only two areas: military and life sciences. Sylvain Berlemont, the founder of Keen Eye chose life sciences and never looked back.
With Patholytix 3.0, Deciphex overcomes one of the last barriers to full-scale adoption of digital pathology.For the first time, users can review and score non-clinical studies on a single platform. The benefit is faster pathology reviews, with less risk of error.OVERCOMING THE LIMITS OF LIMSThe pathology module in existing data management systems is only designed for work with glass slides. Pathologists must purchase a Whole Slide Image Viewer as well as their LIMS system to perform digital reviews.In primary reviews, pathologists would then view the slide on their WSI Viewer and input findings on LIMS. Since there is no syncing between the two systems, human errors can arise with data input.A primary review pathologist would then have to export this report and send it to the peer review pathologist. Next, the peer reviewer would look back and forth between the two systems to find the corresponding findings for the slide he/she is viewing (another potential point of human error).PATHOLYTIX 3.0 FEATURESAUTO SYNC OF SLIDES & FINDINGS Users can review & score studies on the same platformAll findings are automatically associated with the relevant slideFindings can be viewed as text in the grid, or geo-located to exactly where the finding is in the slide – a capability not possible with old Viewer + LIMS system workflowsThere’s no risk of human error with data input. There’s less work involved since users don’t have to manually match a slide with its findings in the LIMS systems.Fully integrated study scoring – an industry firstSIMPLER, FASTER REPORT CREATIONScoring Data is captured in Patholytix in accordance with SEND / INHAND glossariesScoring in this format enables easy transcription into pathology reports and other systems with no additional overheadScoring templates for data entry can be customised for different study typesData is output in a form that’s easiest for report creationREVIEW & SCORE DRUG DISCOVERY STUDIES DIGITALLY FOR THE FIRST TIMEPrior to Patholytix 3.0, most LIMS providers only accommodated for toxicology studies (safety assessment studies). Patholytix 3.0 offers flexible scoring templates and data capture support for drug discovery studies such as TCR, TTC and DRF. No other LIMS can support data capture for such studies.This is the first time ever that a digital pathology platform has enabled the review and scoring of drug discovery studies. Now, users can review these studies digitally, while reaping the benefits of a more efficient workflow.Review tissue microarray studies and other drug discovery studies digitally with PatholytixGEOLOCATED FINDINGSIn Patholytix 3.0, users can score directly on the image they are reviewing (geolocated findings). This capability is not possible in any other LIMS or digital pathology platform.This makes the peer review process quicker as a peer review pathologist knows precisely where to look in the image for the abnormality.Study scoring and review process made simpler with the ability to score directly on slidesREAL-TIME SYNC OF INPUTTED DATAWith Patholytix 3.0, users can score the same study from two different locations and the new scores will be reflected immediately. This is a workflow that could not be possible before.The quicker the review is complete, the quicker a decision can be made on the safety of the drug.DYNAMIC WORKFLOWS FOR GLASS, DIGITAL AND HYBRID STUDIESPatholytix allows users to keep their study findings, be they for glass, digital or hybrid studies, all in one place.This allows you to begin your review immediately using the glass slides while waiting for slides to be scanned. This also means you don’t have to depend on any LIMS to record the findings from your glass slides. You can input these findings in the same place as for your digital slides.SHARE RESULTS INSTANTANEOUSLY.Once primary review is complete, results can be shared with partner organisations instantaneously.Patholytix ends long wait times for shipped slides and large volumes of Customs documentation.NO SHIPPING, NO WAITINGWith Patholytix, there is no sorting, counting, or checking slides for breaks. Findings are inputted to Patholytix (associated with its WSI). The primary review pathologist emails the peer review pathologist once complete. The peer review pathologist begins review.PATHOLYTIX IS CHEAPERNot only is the current LIMS with a built-in pathology module not fit for purpose, but subscription is more expensive. Replacing expensive LIMS pathology modules, the Patholytix 3.0 solution is more cost-effective, and technically better.For more information on the Pathlolytix Data Capture Module, contact sa***@******ex.com or schedule a demo here.SOURCE: Deciphex
Despite numerous advances in our molecular understanding of cancer biology, success in precision medicine trials has remained elusive for many malignancies. Emerging evidence now supports that these challenges are partly driven by proteogenomic discordances across molecular readouts and heterogeneous biology that is spatially distributed across tumors. Here we discuss these key limitations and how integrating the promise of mass-spectrometry-based global proteomics and computational imaging can help prioritize and direct regional sampling to help overcome these important challenges of biologic variation in cancer.
Digital pathology and the scope for machine learning holds great potential workflow efficiencies for veterinary pathologists, as well as for diagnosis and patient care in the wider profession.
Deciphex, a leading provider of pathology software and services, announced today a further €3.9m in funding bringing its full Series B round tally to €14.4m. The additional investment, led by Seroba Life Sciences and existing Deciphex investors, will allow Deciphex to continue developing its innovative products and services, to expand its presence in the UK, Canada, the Middle East and the US, and to strengthen its position as a leader in the field of digital pathology and AI. Jennifer McMahon, a partner with Seroba, will join the Board of Deciphex.
In this episode, I am talking with Don Van Dyke, the chief business officer of Bionovation Biotech. Bionovation holds a patent to a potentially revolutionary scanning technology powered by AI. Due to the ability of the scanner to predict the 3D architecture of the scanned tissue in the Z-axis the device is able to dynamically adjust camera focus exactly to the surface of the specimen and scan it ca. 70x faster than the classical whole slide scanners.
The National Measurement Institutes (NMIs) comprise experts in developing standards and best practices in various domains, including healthcare. To understand the role of standards and measurement science in digital pathology, the National Physical Laboratory (NPL), the UK’s NMI for measurement science, has launched an interdisciplinary project, “Metrology for digital pathology to improve patient outcomes.”
Artificial intelligence (AI) is rapidly fuelling a fundamental transformation in the practice of pathology. However, clinical integration remains challenging, with no AI algorithms to date in routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current expert perspectives and expectations regarding the role of AI in AP from those with first-hand computational pathology and AI experience.
In December, Imogen Fitt of Signify Research attended the 9th Digital Pathology and AI Congress: Europe. In the article below she shares her thoughts on the conference with respect to recent industry discourse.
Proscia®, a leading provider of digital and computational pathology solutions, has announced that the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centers in Europe, will deploy its Concentriq® Dx platform. NKI is transitioning to Concentriq Dx to expand its digital pathology practice, laying the foundation for its pathologists to deliver personalized diagnoses that better inform treatment decisions. In doing so, the cancer center, which houses an internationally acclaimed research institute, will generate additional pathology data that can lead to clinical breakthroughs.
